LINC01818: A Potential Drug Target and Biomarker (G105373684)

Target Name: LINC01818

NCBI ID: G105373684

LINC01818

Other Name(s): Long intergenic non-protein coding RNA 1818, transcript variant X1 | LINC01818 variant X1 | long intergenic non-protein coding RNA 1818

LINC01818: A Potential Drug Target and Biomarker

Non-Protein-Coding RNAs (NP-C RNAs) have been identified as potential drug targets in various diseases. One such RNA, LINC01818, has been shown to have potential as a drug target and biomarker in various diseases, including cancer. In this article, we will explore the biology of LINC01818 and its potential as a drug target and biomarker.

LINC01818 is a Long Intergenic Non-Protein-Coding RNA (lncRNA) with a length of 212 nucleotides. It is located between exons 11 and 12 of human chromosome 16 (16p13.1). LINC01818 is a non-coding RNA that is not translated into protein. However, it is known to play a role in the regulation of gene expression.

LINC01818 is a well-studied lncRNA that has been shown to be involved in various cellular processes, including cell adhesion, migration, and invasion. It is also known to be involved in the regulation of apoptosis, which is a natural cell death mechanism that helps prevent the spread of diseases.

In cancer, LINC01818 has been shown to be involved in the regulation of cell growth and survival. It is also known to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed to provide oxygen and nutrients to cancer cells.

LINC01818 is a potential drug target because of its involvement in cell growth, survival, and angiogenesis. Drugs that target LINC01818 may be effective in treating various diseases, including cancer.

In addition to its potential as a drug target, LINC01818 may also be used as a biomarker for certain diseases. For example, LINC01818 levels may be used as a biomarker for cancer, as higher levels of LINC01818 have been observed in cancer cells compared to healthy cells.

In conclusion, LINC01818 is a well-studied lncRNA that has been shown to be involved in various cellular processes, including cell adhesion, migration, and invasion. It is also known to be involved in the regulation of apoptosis and angiogenesis. As a result, LINC01818 may be a potential drug target and biomarker for various diseases, including cancer. Further research is needed to fully understand the role of LINC01818 in disease.

Protein Name: Long Intergenic Non-protein Coding RNA 1818

The "LINC01818 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01818 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets